Losartan

Generic Name
Losartan
Brand Names
Hyzaar, Cozaar
Drug Type
Small Molecule
Chemical Formula
C22H23ClN6O
CAS Number
114798-26-4
Unique Ingredient Identifier
JMS50MPO89
Background

Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Losartan is available as losartan potassium oral tablets as well as a combination tablet of losartan potassium and hydrochlorothiazide. Patients taking losartan should have their renal function and potassium levels monitored. Losartan was granted FDA approval on 14 April 1995.

Indication

Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hypertension. Losartan with hydrochlorothiazide is indicated to treat hypertension and to reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage).

Associated Conditions
Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke
Associated Therapies
-

Influence of Aliskiren on Albuminuria After Kidney Transplantation

Not Applicable
Completed
Conditions
Interventions
First Posted Date
2015-05-18
Last Posted Date
2015-05-18
Lead Sponsor
Medical University of Gdansk
Target Recruit Count
18
Registration Number
NCT02446548
Locations
🇵🇱

Medical University of Gdansk, Gdansk, Pomorskie, Poland

Intervention Using Vitamin D for Elevated Urinary Albumin Treated With Losartan in Diabetes (IDEAL)

First Posted Date
2015-04-07
Last Posted Date
2017-06-15
Lead Sponsor
Weill Cornell Medical College in Qatar
Target Recruit Count
56
Registration Number
NCT02410005
Locations
🇶🇦

Weill Cornell Medical College in Qatar, Doha, Qatar

🇶🇦

Hamad Medical Corporation, Doha, Qatar

🇺🇸

Weill Cornell Medical College, New York, New York, United States

Preventing Sickle Cell Kidney Disease

First Posted Date
2015-02-26
Last Posted Date
2024-04-03
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
1
Registration Number
NCT02373241
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

Phase 1/2 Prospective Double-Blind Placebo-Controlled Randomized Clinical Trial of Losartan to Treat Grade II & III Hamstring Strains

Phase 1
Terminated
Conditions
Interventions
First Posted Date
2014-10-13
Last Posted Date
2024-05-02
Lead Sponsor
James J. Irrgang
Target Recruit Count
8
Registration Number
NCT02263729
Locations
🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

Efficacy and Safety Evaluating Study to Compare Kanarb (Fimasartan) and Cozaar® (Losartan) in Adult Patients With Grade I-II Arterial Hypertension

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-09-25
Last Posted Date
2019-05-06
Lead Sponsor
R-Pharm
Target Recruit Count
179
Registration Number
NCT02248961
Locations
🇷🇺

Moscow Health Department "City Clinical Hospital № 81", Moscow, Russian Federation

🇷🇺

St. Petersburg State healthcare Institution "City Hospital number 28" "Maximilianovskaya", St. Petersburg, Russian Federation

🇷🇺

St. Petersburg State Healthcare Institution 'Diagnostic Centre #85', St. Petersburg, Russian Federation

and more 10 locations

An Efficacy and Safety Study in Children 6 to Less Than 18 Years of Age With Hypertension

First Posted Date
2014-09-10
Last Posted Date
2023-02-16
Lead Sponsor
Arbor Pharmaceuticals, Inc.
Target Recruit Count
215
Registration Number
NCT02235909
Locations
🇧🇷

Fundação José Luiz Egydio Setúbal, São Paulo, Brazil

🇺🇸

Pioneer Clinical Research, North Miami, Florida, United States

🇺🇸

Georgia Clinical Research, Snellville, Georgia, United States

and more 66 locations

Efficacy and Safety of Losartan in Pediatric Chronic Kidney Disease With Tubular Proteinuria

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-09-05
Last Posted Date
2018-10-10
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
58
Registration Number
NCT02232763
Locations
🇰🇷

Seoul National University Children's Hospital, Seoul, Korea, Republic of

Efficacy and Safety of Losartan in Children With Ig A Nephropathy

Phase 3
Completed
Conditions
Interventions
First Posted Date
2014-09-05
Last Posted Date
2018-10-10
Lead Sponsor
Seoul National University Hospital
Target Recruit Count
37
Registration Number
NCT02232776
Locations
🇰🇷

Seoul National University Children's Hospital, Seoul, Korea, Republic of

Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy

First Posted Date
2014-09-04
Last Posted Date
2016-07-06
Lead Sponsor
Chen Xiangmei
Target Recruit Count
1600
Registration Number
NCT02231125
Locations
🇨🇳

Guang An Men Hospital China Academy of Chinese Medical Sciences, Beijing, Beijing, China

🇨🇳

Jilin Province People's Hospital, Changchun, Jilin, China

🇨🇳

Ningxia Hui Autonomous Region's Hospital, Yinchuan, Ningxia, China

and more 85 locations

Residual Renal Function Preservation in Peritoneal Dialysis Patients

First Posted Date
2014-07-15
Last Posted Date
2014-08-01
Lead Sponsor
Second Xiangya Hospital of Central South University
Target Recruit Count
96
Registration Number
NCT02190318
© Copyright 2024. All Rights Reserved by MedPath